Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933570 | 0.90 | HRH4 (0.39) | HRH3SIGMAR1ACHESLC6A3LTA4H | |
| SCHEMBL3180816 | 0.77 | SIGMAR1 (0.44) | HRH3SIGMAR1CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL12005483 | 0.72 | ACHE (0.51) | HRH3L3MBTL1TDP1SIGMAR1ACHE | |
| SCHEMBL3184549 | 0.72 | HRH1 (0.36) | TDP1ALOX15 | |
| SCHEMBL11612846 | 0.72 | AOC1 (0.35) | — | |
| SCHEMBL529621 | 0.71 | HRH3 (0.51) | HRH3L3MBTL1TDP1SIGMAR1CYP1A2 | |
| SCHEMBL29519954 | 0.71 | HRH3 (0.46) | HRH3L3MBTL1TDP1SIGMAR1CYP1A2 | |
| SCHEMBL27925347 | 0.71 | HRH3 (0.62) | HRH3L3MBTL1TDP1SIGMAR1CYP1A2 | |
| SCHEMBL18940336 | 0.71 | ACHE (0.50) | HRH3L3MBTL1SIGMAR1ACHECYP1A2 | |
| SCHEMBL23245930 | 0.71 | DHFR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105218561-B | Annelated pyrimidines ring derivatives, preparation method and application | 上海艾力斯医药科技有限公司 | 2018-10-30 | — | — | CN | disclosed |
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | HRH3 72/4885L3MBTL1 4344/4885TDP1 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.